Home
IDYA
IDYA News

Latest IDEAYA Biosciences Inc. (IDYA) News on December 18, 2024

MT Newswires

a day ago

IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

PR Newswire

a day ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

PR Newswire

2 days ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

Simply Wall St.

2 days ago

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

PR Newswire

7 days ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

PR Newswire

8 days ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

MT Newswires

9 days ago

IDEAYA Biosciences Nominates IDE892 as Development Candidate

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

PR Newswire

9 days ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

12 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

PR Newswire

16 days ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

19 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey

a month ago

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

PR Newswire

a month ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

PR Newswire

a month ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

MT Newswires

a month ago

IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Business Wire

a month ago

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

PR Newswire

a month ago

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

Zacks

a month ago

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

MT Newswires

a month ago

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

Simply Wall St.

a month ago

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

PR Newswire

a month ago

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

MT Newswires

a month ago

IDEAYA Biosciences Q3 Loss Narrows

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

2 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Zacks

2 months ago

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

Zacks

2 months ago

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

MT Newswires

2 months ago

IDEAYA Biosciences Secures FDA Approval for IDE275's Investigational New Drug Application

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

PR Newswire

2 months ago

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

MT Newswires

2 months ago

IDEAYA Biosciences Reports 'Positive' Interim Phase 1 Data for Cancer Drug; Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

PR Newswire

2 months ago

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

MT Newswires

2 months ago

UBS Initiates IDEAYA Biosciences With Buy Rating, $50 Price Target

MT Newswires

2 months ago

Cantor Fitzgerald Initiates IDEAYA Biosciences at Overweight

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

PR Newswire

2 months ago

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

3 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

Clinical Trials Arena

3 months ago

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

MT Newswires

3 months ago

Wedbush Trims Price Target on IDEAYA Biosciences to $52 From $54, Keeps Outperform Rating

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires

3 months ago

Ideaya Biosciences Says Phase 2 Darovasertib Trial Showed 'Clinically Meaningful' Results

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

PR Newswire

3 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

PR Newswire

3 months ago

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

PR Newswire

3 months ago

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire

4 months ago

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

Simply Wall St.

4 months ago

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Simply Wall St.

4 months ago

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

MT Newswires

4 months ago

Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $60, Maintains Outperform Rating

MT Newswires

4 months ago

IDEAYA Biosciences Shares Gain After Company Reports Q2 Net Loss

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

PR Newswire

4 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

5 months ago

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

MT Newswires

5 months ago

IDEAYA Biosciences, Biocytogen Agree to Option, License Deal for Solid Tumors Treatment Program

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

PR Newswire

5 months ago

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Business Wire

5 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Business Wire

5 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

PR Newswire

5 months ago

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

Zacks

5 months ago

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

MT Newswires

5 months ago

Wedbush Cuts Price Target on IDEAYA Biosciences to $54 From $56, Maintains Outperform Rating

Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts

Simply Wall St.

5 months ago

Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts

MT Newswires

5 months ago

JPMorgan Raises Price Target on IDEAYA Biosciences to $69 From $65, Maintains Overweight Rating

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire

5 months ago

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Zacks

5 months ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

MT Newswires

5 months ago

RBC Raises Price Target on IDEAYA Biosciences to $61 From $53, Keeps Outperform, Speculative Risk

MT Newswires

5 months ago

IDEAYA Biosciences Prices $263 Million Public Offering

IDEAYA Announces Pricing of Public Offering

PR Newswire

5 months ago

IDEAYA Announces Pricing of Public Offering

MT Newswires

5 months ago

IDEAYA Biosciences Plans to Sell Shares, Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire

5 months ago

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Zacks

5 months ago

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Company News for July 9, 2024

Zacks

5 months ago

Company News for July 9, 2024

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

Zacks

5 months ago

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment

Clinical Trials Arena

5 months ago

IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment

Top Stock Movers Now: Intel, Corning, SolarEdge, and More

Investopedia

5 months ago

Top Stock Movers Now: Intel, Corning, SolarEdge, and More

IDEAYA Biosciences Soars on Cancer Drug Study Results

Investopedia

5 months ago

IDEAYA Biosciences Soars on Cancer Drug Study Results

MT Newswires

5 months ago

Wedbush Raises Price Target on IDEAYA Biosciences to $56 From $52, Maintains Outperform Rating

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March

Investor's Business Daily

5 months ago

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March

MT Newswires

5 months ago

Ideaya Biosciences Reports Positive Results for Potential Non-Small Cell Lung Cancer Treatment -- Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

PR Newswire

5 months ago

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

MT Newswires

5 months ago

Mizuho Securities Initiates IDEAYA Biosciences at Outperform With $50 Price Target

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

PR Newswire

5 months ago

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

6 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial

Clinical Trials Arena

6 months ago

IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

PR Newswire

6 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

PR Newswire

6 months ago

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years

Simply Wall St.

6 months ago

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

6 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

6 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

6 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

6 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

6 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

6 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

6 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

6 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

MT Newswires

6 months ago

Stifel Adjusts Price Target on IDEAYA Biosciences to $63 From $55, Maintains Buy Rating

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

PR Newswire

6 months ago

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

MT Newswires

6 months ago

Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events

PR Newswire

7 months ago

IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development

PR Newswire

7 months ago

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

PR Newswire

7 months ago

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

MT Newswires

7 months ago

Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing

MT Newswires

7 months ago

Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating

IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

Simply Wall St.

7 months ago

IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

Share on Social Networks: